Oslo, Norway, 9 September 2025. EXACT Therapeutics (Euronext Growth: EXTX), a
clinical-stage precision medicine company, is pleased to announce that early,
encouraging pre-clinical data on EXACT's proprietary Acoustic Cluster Therapy
(ACT®) in immune oncology will be presented at the upcoming Ninth International
Cancer lmmunotherapy Conference (CICON25), during September 10-12, 2025, in
Utrecht, The Netherlands. 

The following two posters will be presented:

o Title: Acoustic Cluster Therapy (ACT) increases Anti-PD1 checkpoint inhibitor
uptake in prostate 
  cancer in mice 
o In collaboration with NTNU, the Norwegian University of Science and Technology

o Title: Evaluation of the immunostimulatory potential of Acoustic Cluster
Therapy (ACT®) in melanoma 
  and breast cancer models in mice
o In collaboration with ICR, the Institute of Cancer Research, UK


The posters will be made available on the Company's website.

About EXACT Therapeutics:

EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound and microbubbles to enable targeted drug delivery in
oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be
applied to a wide range of therapeutic agents within oncology and across a
multitude of other indications, including brain diseases. EXACT Therapeutics'
shares are traded on Euronext Growth Oslo (EXTX). Further information may be
found here: www.exact-tx.com   

For further information, please contact:

Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com